肾功能不全时肌钙蛋白的解读:急诊临床医生叙事综述
该叙事综述评估了慢性肾脏病(CKD)/终末期肾病(ESRD)患者肌钙蛋白升高的原因、使用肌钙蛋白评估时的陷阱及处理策略。CKD/ESRD患者急性冠脉综合征(ACS)风险更高、循环肌钙蛋白水平更高且常表现不典型;肌钙蛋白升高可源于尿毒症性骨骼肌病、微梗死、左心室肥厚(LVH)、清除减少及未识别的充血性心力衰竭(CHF)等多种病因。肌钙蛋白检测在该人群中的敏感性和特异性不一,需细致解读;对肌钙蛋白升高且怀疑ACS者,应给予ACS治疗直至排除,并考虑不典型表现及其他可致肌钙蛋白升高的症状原因。
要点
- CKD/ESRD患者ACS风险更高且循环肌钙蛋白水平更高,常以不典型方式就诊。
- 肌钙蛋白升高不能一概归因于肾病,病因包括尿毒症性骨骼肌病、微梗死、左心室肥厚、清除减少及未识别的充血性心力衰竭。
- 肌钙蛋白检测在CKD人群中的敏感性和特异性不一,需结合临床细致解读。
- 对肌钙蛋白升高且怀疑ACS的CKD/ESRD患者,应给予ACS治疗直至排除。
- 评估时应同时考虑不典型表现及其他可导致肌钙蛋白升高的症状原因。
适用人群与场景
- 慢性肾脏病(CKD)/终末期肾病(ESRD)患者,出现怀疑急性冠脉综合征(ACS)的症状时。
- 急诊科就诊的CKD/ESRD患者。
处置流程与药物剂量
- 对肌钙蛋白升高且怀疑ACS的CKD/ESRD患者,应给予ACS治疗直至排除。
- 评估时需考虑不典型表现及其他可致肌钙蛋白升高的症状原因。
研究设计与关键结果
- CKD/ESRD患者ACS风险更高,循环肌钙蛋白水平更高,且常表现不典型。
- 肌钙蛋白升高病因包括尿毒症性骨骼肌病、微梗死、左心室肥厚(LVH)、清除减少及未识别的充血性心力衰竭(CHF)。
- 肌钙蛋白检测在CKD人群中的敏感性和特异性不一。
证据类型、等级与局限
- 证据类型:叙事综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对CKD/ESRD患者疑似ACS时,不应仅因存在肾病而将肌钙蛋白升高归因于肾功能不全,需考虑多种病因。
- 对肌钙蛋白升高且怀疑ACS者,应给予ACS治疗直至排除(原文推荐)。
- 评估时需注意CKD/ESRD患者ACS表现可不典型,并排查其他导致肌钙蛋白升高的原因。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Patients with chronic kidney disease (CKD)/end stage renal disease (ESRD) can experience several severe complications, including acute coronary syndrome (ACS). While troponin is the biomarker of choice for evaluation of ACS, interpretation of troponin in CKD/ESRD can be challenging.
OBJECTIVE: This narrative review evaluates troponin elevation in patients with CKD/ESRD, pitfalls in the evaluation with troponin, and an approach to using troponin in these high-risk patients.
DISCUSSION: Patients with CKD/ESRD are at greater risk for ACS and possess higher levels of circulating troponin. Relatedly, these patients often present atypically for ACS. Several pitfalls must be considered in the use of troponin when evaluating for ACS. While troponin elevation in patients with CKD/ESRD is often considered to be due to underlying renal disease, this elevation has several etiologies including uremic skeletal myopathy, microinfarctions, left ventricular hypertrophy (LVH), decreased clearance, and unrecognized congestive heart failure (CHF). Utilizing troponin assays in this patient population requires a nuanced approach, as the sensitivity and specificity for troponin testing in CKD varies. Concern for ACS with elevated troponin warrants treatment for ACS until proven otherwise, with consideration of atypical presentations along with other causes for patient symptoms that may result in troponin elevation.
CONCLUSIONS: Patients with CKD/ESRD presenting with symptoms concerning for ACS are challenging. The utilization of troponin assays is important in this population given their high risk of ACS but requires an educated and nuanced approach.
参考来源
- Long B, Belcher CN, Koyfman A, et al. Interpreting troponin in renal disease: A narrative review for emergency clinicians. Am J Emerg Med. 2019. PMID: 31831340. doi:10.1016/j.ajem.2019.11.041
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。